Blazing a New Path in Medicine

Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for cancer.

Nurix was founded by a team of internationally renowned experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development and cancer therapy. Through its leadership in Targeted Protein Modulation and its powerful proprietary DELigase platform, Nurix has attracted industry-leading partners including its current drug discovery collaborations with Sanofi and Gilead Sciences.

Michael Lotze

Michael T. Lotze, M.D.

Chief Cellular Therapy Officer

Michael T. Lotze, M.D. has served as Chief Cellular Therapy Officer of Nurix since June 2020. He is a leading clinician scientist with more than 30 years of experience in immunology and clinical medicine, dedicating his efforts to the advancement of translational research, particularly in immunotherapy for cancer including dendritic cell, T cell, and cytokine therapies. Dr. Lotze is the co-inventor of multiple patents in dendritic cell vaccines and antigen discovery, and tumor infiltrating lymphocyte therapy. He previously held leadership roles in the biopharmaceutical industry as the chief scientific officer of Iovance Biotherapeutics and vice president of research at GlaxoSmithKline. Prior to joining Nurix, Dr. Lotze served as professor of surgery, immunology, and bioengineering, vice chair of research within the Department of Surgery and director for Damage Associated Molecular Pattern Molecule (DAMP) Laboratories at the University of Pittsburgh Medical Center Hillman Cancer Center. He was also senior advisor for the Immune Transplant and Therapy Center within the University of Pittsburgh Medical Center Enterprises and serves as associate editor of the Journal of Immunotherapy. Over the course of his career, he has authored more than 500 publications and several books. Dr. Lotze holds an M.D. from Northwestern University and completed his postdoctoral training as a scientist at the National Cancer Institute under Dr. Steven Rosenberg.